La chaîne d'options affiche les données clés des options sur actions de Mineralys Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Mineralys Therapeutics..

Mineralys Therapeutics (NASDAQ:MLYS) Stock, Chaîne d'Options

MINERALYS THERAPEUTICS INC

Mineralys Therapeutics

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics Inc

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45372571/anthony-scaramucci-says-bitcoin-is-evolving-from-a-tech-asset-to-digital-gold">extreme volatility</a> makes it unsuitable as a benchmark for liquid funds, according to a new report from RedStone Oracles.
What Happened: Authored by Marcin Kaźmierczak, the report argues that while Bitcoin has delivered headline-grabbing returns, its risk-adjusted performance disqualifies it as a standard for measuring the success of capital preservation strategies.
The analysis shows that Bitcoin's Sharpe ratio ranged from -6.58 to 6.97, and 25% of observations fell below -1.20, metrics that signal high capital risk and inconsistency.
These traits contradict the core objectives of liquid funds, which prioritize stability, capital efficiency and liquidity.
&#8220;Volatility, risk appetite, and investment horizons reveal why benchmarking every fund to the Bitcoin performance is fundamentally flawed,&#8221; Kaźmierczak wrote, noting that return rates alone offer a dangerously incomplete picture.
Even when compared to growth-oriented traditional indices like the S&amp;P 500, which itself may be too volatile for many liquid fund mandates, Bitcoin underperforms in terms of stability. 
The report notes that Bitcoin saw a -49.22% drawdown between January and September 2024, while the S&amp;P 500&#8217;s largest decline during the same period was -15.59%.
The standard deviation of Bitcoin's Sharpe ratio, calculated at 2.72, highlights frequent oscillations between extreme gains and severe losses.
These sharp swings, the report argues, expose portfolios to unacceptable downside risk, especially for funds with short-term liquidity requirements.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45409339/jpmorgan-completes-first-public-trade-of-tokenized-treasuries">JPMorgan Completes First Public Trade Of Tokenized Treasuries</a>
Why It Matters: Kaźmierczak also emphasizes the difference in performance evaluation frameworks now emerging in on-chain finance.
Platforms like Morpho and Euler are enabling fund managers to structure "vaults" that optimize for liquidity, yield, and risk.
While returns from these platforms may trail simple BTC holding strategies, they represent a more sustainable approach by adopting professional-grade risk frameworks.
By using 30-day rolling Sharpe ratios and controlling for trading days, the report builds a time-synchronized performance model, underscoring the need to consider risk-adjusted returns rather than chasing linear growth metrics.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405649/the-curious-story-behind-the-melania-trump-meme-coin-launch">The Curious Story Behind The Melania Trump Meme Coin Launch</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

Bitcoin's Volatility Makes It Unfit As A Benchmark For Liquid Funds: Report

Ladenburg Thalmann analyst Mickey Schleien downgrades Gladstone Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIN#NASDAQ">GAIN</a>) from Buy to Neutral.

Downgrades

Analyst Ratings

GAIN

Ladenburg Thalmann Downgrades Gladstone Inv to Neutral

Roth MKM analyst Richard Baldry reiterates SoundThinking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSTI#NASDAQ">SSTI</a>) with a Buy and maintains $30 price target.

Price Target

Reiteration

SSTI

Roth MKM Reiterates Buy on SoundThinking, Maintains $30 Price Target

HC Wainwright &amp; Co. analyst Robert Burns maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy and lowers the price target from $145 to $134.

BNTX

HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $134

Lake Street analyst Thomas Flaten maintains Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) with a Buy and lowers the price target from $3 to $2.

BDSX

Lake Street Maintains Buy on Biodesix, Lowers Price Target to $2

Roth MKM analyst Chip Moore reiterates EnerSys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENS#NYSE">ENS</a>) with a Buy and maintains $120 price target.

Roth MKM Reiterates Buy on EnerSys, Maintains $120 Price Target

Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) has <a target="_blank" href="https://www.benzinga.com/topic/autonomous-driving" rel="noreferrer noopener">confidentially filed for</a> a Hong Kong initial public offering to help raise capital to expand its business.
The autonomous-driving company filed for listing to limit the impact on Pony AI&#8217;s U.S.-traded shares, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-05-14/pony-ai-is-said-to-confidentially-file-for-hong-kong-listing?srnd=indus&amp;sref=TBDibEcD" rel="noreferrer noopener">reported</a> Wednesday, citing unnamed sources familiar with the matter.
The stock price soared in Wednesday&#8217;s premarket session before giving up the gains.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/04/45013465/pony-ai-and-tencent-partner-on-l4-robotaxis-expand-chinas-self-driving-future" rel="noreferrer noopener">Pony.ai And Tencent Partner On L4 Robotaxis, Expand China&#8217;s Self-Driving Future</a>
A&nbsp;Pony AI&#8217;s robotaxi caught ablaze for the first time on Tuesday, CNBC <a target="_blank" href="https://www.cnbc.com/2025/05/14/chinese-robotaxi-operator-ponyai-reports-first-fire-no-injuries.html" rel="noreferrer noopener">reported</a> on Wednesday, citing the company. No passengers were on board during the incident, and the vehicle automatically initiated an emergency stop, resulting in no collisions or injuries.
Pony AI told CNBC that it detected one of its fully self-driving vehicles as having an abnormal status in Beijing around 9:30 a.m. local time on May 13.
The company&nbsp;had raised&nbsp;~$413 million in a U.S. initial public offering and concurrent private placements in November 2024.
Pony AI stock surged 50% in the last 12 months. In April, Pony AI chief technology officer&nbsp;Lou Tiancheng told&nbsp;The Wall Street Journal&nbsp;that the company is <a target="_blank" href="https://www.benzinga.com/news/global/25/04/45049945/pony-ai-stock-is-galloping-higher-monday-heres-what-investors-are-watching" rel="noreferrer noopener">getting closer to</a> breakeven following cost-cutting measures.
Following the release of three new robotaxis at the Shanghai Auto Show last week,&nbsp;company executives reportedly said Pony AI could build its most advanced autonomous driving systems for 70% less than before.
Analysts said that Pony AI could reach single-unit breakeven goals by the end of 2025.
Reportedly, Pony AI plans to commercialize its robotaxis by mid-2025 and is targeting to add 700 vehicles to its fleet by the end of the year.
Last week, Pony AI tapped Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>)&nbsp;to <a target="_blank" href="https://www.benzinga.com/25/05/45225030/robotaxis-take-the-wheel-pony-ai-and-uber-team-up-for-international-rollout" rel="noreferrer noopener">launch robotaxi services</a> in the Middle East.
Price Action: PONY stock is down 8.08% to $16.50 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45325248/lyft-is-executing-well-but-analysts-caution-about-uber-and-waymo-competition" target="_blank" rel="noreferrer noopener">Lyft Is Executing Well But Analysts Caution About Uber And Waymo Competition</a></li>
</ul>
Photo by Tada Images via Shutterstock

Asia

Emerging Markets

IPOs

Movers

Tech

Media

PONY

UBER

Robotaxi Service Pony AI Stock Falls Despite IPO Buzz - Here's Why

Roth MKM analyst Jeff Martin maintains Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) with a Buy and lowers the price target from $6 to $5.

TACT

Roth MKM Maintains Buy on Transact Technologies, Lowers Price Target to $5

Lake Street analyst Eric Martinuzzi maintains SoundThinking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSTI#NASDAQ">SSTI</a>) with a Buy and raises the price target from $18 to $20.

Lake Street Maintains Buy on SoundThinking, Raises Price Target to $20

Cisco Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) will report its<a href="https://www.benzinga.com/quote/CSCO/earnings"> third-quarter earnings</a> Wednesday after the market close, with Wall Street expecting earnings per share of 92 cets and revenue of $14.08 billion.
The stock has climbed 25.4% over the past year, despite being down 3.87% year-to-date and slipping 6.92% in the past month. However, over the last five trading days, Cisco stock has regained 2.53%, and a confluence of bullish technical signals suggests momentum may just be heating up.
Let's take a look at what's propelling Cisco's stock and how the charts are setting up ahead of earnings.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/05/45398341/how-to-earn-500-a-month-from-cisco-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Cisco Stock Ahead Of Q3 Earnings</a>
<h1 class="wp-block-heading">A Strategic AI Infusion</h1>
Cisco just <a href="https://newsroom.cisco.com/c/r/newsroom/en/us/a/y2025/m05/cisco-appoints-kevin-weil-to-its-board-of-directors.html">added</a> a major dose of AI credibility to its board, appointing Kevin Weil, Chief Product Officer at OpenAI, effective May 12. Weil's resume includes product leadership at X (formerly Twitter), Instagram and now OpenAI — the company behind ChatGPT. CEO Chuck Robbins said that Cisco would "leverage his deep expertise in AI and product innovation to guide our strategic initiatives."
That's not all. Cisco also <a href="https://newsroom.cisco.com/c/r/newsroom/en/us/a/y2025/m05/cisco-announces-new-strategic-ai-initiatives-in-the-middle-east.html?source=rss">announced</a> an expanded partnership with Saudi Arabia's HUMAIN AI, aiming to power the Kingdom's AI infrastructure under <a href="https://www.prnewswire.com/news-releases/cisco-expands-partnership-with-saudi-arabia-to-power-the-ai-future-302454263.html">Vision 2030</a>. Additional collaborations with G42 and the AI Infrastructure Partnership (AIP) across the UAE and the U.S. further entrench Cisco in the global AI arms race.
<h1 class="wp-block-heading">Cisco Stock Strongly Bullish Ahead Of Q3 Earnings</h1>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14122028/Screenshot-2025-05-14-at-9.31.53-PM.png" alt="" class="wp-image-915348" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14122028/Screenshot-2025-05-14-at-9.31.53-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14122028/Screenshot-2025-05-14-at-9.31.53-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Cisco stock at $61.38 trades decisively above its eight-, 20-, 50- and 200-day simple moving averages, triggering a string of bullish technical signals. The eight-day SMA sits at $60.30, the 20-day at $58.07, the 50-day at $59.13 and the 200-day at $56.79 — all beneath the current price.
The Moving Average Convergence Divergence (MACD) indicator clocks in at 0.79, further reinforcing the bullish momentum. Meanwhile, the Relative Strength Index (RSI) is at 64.67 — elevated, but not yet in overbought territory.
<h1 class="wp-block-heading">Cisco Analysts See 9% Upside</h1>
Cisco Analysts Ratings &amp; Consensus Estimates: The <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">consensus rating</a> on Cisco stock stands at Buy, with an average price target of $62.65. Recent bullish sentiment from top Wall Street firms reinforces that view. 
The three most recent analyst updates — from Evercore ISI Group, Rosenblatt and JPMorgan — carry an average price target of $66.67, implying an upside of roughly 8.66% from current levels.
CSCO Price Action: Cisco stock was trading down 1.25% at $61.01 at the time of publication on Wednesday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45405041/ciscos-partners-with-aip-in-latest-ai-push">Cisco&#8217;s Partners With AIP In Latest AI Push</a></li>
</ul>
Photo: Shutterstock

Technicals

Previews

Trading Ideas

CSCO

Cisco Stock Roars Back On AI Firepower, Saudi Pact — Bullish Breakout Faces Q3 Earnings Test

Roth MKM analyst Jeff Martin upgrades Perion Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PERI#NASDAQ">PERI</a>) from Neutral to Buy and raises the price target from $9 to $14.

Upgrades

PERI

Roth MKM Upgrades Perion Network to Buy, Raises Price Target to $14

Lake Street analyst Jaeson Schmidt maintains BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) with a Buy and raises the price target from $51 to $55.

BKTI

Lake Street Maintains Buy on BK Technologies, Raises Price Target to $55

ABBV

AbbVie Announces That EMRELIS Has Been Granted Accelerated Approval By The FDA For The Treatment Of Adult Patients With Locally Advanced Or Metastatic, Non-Squamous Non-Small Cell Lung Cancer With High C-Met Protein Overexpression  Who Have Received A Prior Systemic Therapy

WIIM

RKLB

Rocket Lab shares are trading higher after the company on Wednesday announced the return of its Pioneer spacecraft for Varda Space Industries.

Lake Street analyst Eric Martinuzzi maintains Perion Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PERI#NASDAQ">PERI</a>) with a Buy and raises the price target from $10.5 to $13.

Lake Street Maintains Buy on Perion Network, Raises Price Target to $13

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with a Buy and lowers the price target from $20 to $16.

ACRS

HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $16

NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) will release its quarterly earnings report on Thursday, 2025-05-15. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate NRX Pharmaceuticals to report an earnings per share (EPS) of $-0.40.
Investors in NRX Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Here's a look at NRX Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td>-0.69</td>
<td>-0.58</td>
<td>-0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.77</td>
<td>-0.15</td>
<td>-0.75</td>
<td>-0.74</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.000000000000001%</td>
<td>3.0%</td>
<td>-6.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<h3>Performance of NRX Pharmaceuticals Shares</h3>
Shares of NRX Pharmaceuticals were trading at $2.29 as of May 13. Over the last 52-week period, shares are down 37.22%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/NRXP/earnings">To track all earnings releases for NRX Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

NRXP

Uncovering Potential: NRX Pharmaceuticals's Earnings Preview

cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-15. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect cbdMD to report an earnings per share (EPS) of $-0.36.
cbdMD bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Here's a look at cbdMD's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td>0</td>
<td>-0.62</td>
<td>-0.75</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.22</td>
<td>-0.18</td>
<td>-0.15</td>
<td>-1.35</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-15.0%</td>
<td>-7.000000000000001%</td>
<td>2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<h3>Market Performance of cbdMD's Stock</h3>
Shares of cbdMD were trading at $1.01 as of May 13. Over the last 52-week period, shares are down 82.75%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/YCBD/earnings">To track all earnings releases for cbdMD visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

YCBD

An Overview of cbdMD's Earnings

Airbnb Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) shares are trending Wednesday following the company's announcement of a <a href="https://www.benzinga.com/general/travel/25/05/45414358/3-airbnb-initiatives-that-could-unleash-growth-opportunities">major platform expansion</a>.
What To Know: The company introduced Airbnb Services and Airbnb Experiences, along with a redesigned app that integrates bookings for homes, services and activities in a single interface.The updates aim to expand Airbnb's business beyond lodging. 
&#8220;Seventeen years ago, we changed the way people travel. More than two billion guests later, Airbnb is synonymous with a place to stay. With the launch of services and experiences, we're changing travel again. Now you can Airbnb more than an Airbnb,&#8221; said Brian Chesky, co-founder and CEO of Airbnb.
Airbnb Services includes offerings like in-home chefs, massages, personal training and spa treatments, launching in 260 cities across 10 categories. Airbnb Services will be available at nearly every price, and many services will offer an entry level below $50.
Airbnb Experiences, reimagined with new standards and original content, allows users to book activities hosted by local experts. Experiences range from cultural tours and culinary workshops to sessions hosted by celebrities. The company is launching Experiences in 650 cities globally and plans to add more offerings daily.
Airbnb also unveiled a redesigned app interface featuring real-time itinerary management, a new Explore tab and improved host tools. The company also rebuilt the app for hosts to include everything needed to manage their homes, services or experiences.
The rollout reflects Airbnb's effort to grow its presence in the broader travel and lifestyle market. Chesky described the expansion as a shift from being a platform for booking stays to one offering a complete trip experience. 
The new features are available starting this week and hots can access upgrades by enrolling in Airbnb Early Access in the app.
ABNB Price Action: Airbnb has a 52-week high of $163.93 and a 52-week low of $99.88. Airbnb shares experienced a significant decline of close to 40% from its highs in February to its lows in early April. The stock has rebounded more than 30% off the April lows. Shares were up 0.47% at $138.70 at the time of publication Wednesday, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45406180/only-half-of-sp-500-stocks-joined-the-tariff-relief-rally-time-to-buy-the-laggards">Only Half Of S&amp;P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards? </a></li>
</ul>
Image Via Shutterstock.

ABNB

What's Going On With Airbnb Stock Today?

Loop Capital analyst Timothy Greaves maintains Porch Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) with a Buy and raises the price target from $6 to $13.

PRCH

Loop Capital Maintains Buy on Porch Group, Raises Price Target to $13

Press Releases

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Health Care

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Comments

Mineralys Therapeutics

Mineralys Therapeutics (MLYS) Options

Loading...

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL